Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 193

Results For "NIT"

5875 News Found

Fluor to provide EPCM services for pharmaceutical facility in Indiana
News | April 07, 2025

Fluor to provide EPCM services for pharmaceutical facility in Indiana

This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202


Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
News | April 07, 2025

Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US

Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013


Lupin acquires UK-based Renascience Pharma for £12.3 million
News | April 04, 2025

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases


Gland Pharma receives approval for Acetaminophen Injection
Drug Approval | April 04, 2025

Gland Pharma receives approval for Acetaminophen Injection

The company expects to launch this product through its marketing partner in the near future


Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
News | April 04, 2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study


AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Drug Approval | April 04, 2025

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone


Enhertu approved in EU in post-ET breast cancer
Drug Approval | April 04, 2025

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease


Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025
News | April 04, 2025

Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025

Awards highlight Avantor's commitment to the Biopharma industry